<br/ >1. Ability to provide written informed consent. <br/ >2. Participants of either gender of age between �18 to �60 years. <br/ >3. Good general health as determined by the discretion of investigator (vital signs (heart rate �60 to�100 bpm, blood pressure systolic �90 mm Hg and <140 mm Hg, diastolic � 60 mm Hg and <90 mm Hg, oral temperature <100.4ºF), medical history, and physical examination). <br/ >4. Expressed interest and availability to fulfil the study requirements. <br/ >5. For a female participant of child-bearing potential, planning to avoid becoming pregnant (use of an effective method of contraception or abstinence) from the time of study enrolment until at least four weeks after the last vaccination. <br/ >6. Male subjects of reproductive potential: Use of condoms to ensure effective contraception with the female partner from first vaccination until 3 months after last vaccination. <br/ >7. Male subjects agree to refrain from sperm donation from the time of first vaccination until 3 months after last vaccination. <br/ >8. Participants must refrain from blood or plasma donation from the time of first vaccination until 3 months after last vaccination. <br/ >9. Agrees not to participate in another clinical trial at any time during the study. <br/ >10. Agrees to remain in the study area for the entire duration of the study. <br/ >11. Willing to allow storage and future use of biological samples for future research. <br/ >

<br/ >1. Ability to provide written informed consent. <br/ >2. Participants of either gender of age between �18 to �60 years. <br/ >3. Good general health as determined by the discretion of investigator (vital signs (heart rate �60 to�100 bpm, blood pressure systolic �90 mm Hg and <140 mm Hg, diastolic � 60 mm Hg and <90 mm Hg, oral temperature <100.4ºF), medical history, and physical examination). <br/ >4. Expressed interest and availability to fulfil the study requirements. <br/ >5. For a female participant of child-bearing potential, planning to avoid becoming pregnant (use of an effective method of contraception or abstinence) from the time of study enrolment until at least four weeks after the last vaccination. <br/ >6. Male subjects of reproductive potential: Use of condoms to ensure effective contraception with the female partner from first vaccination until 3 months after last vaccination. <br/ >7. Male subjects agree to refrain from sperm donation from the time of first vaccination until 3 months after last vaccination. <br/ >8. Participants must refrain from blood or plasma donation from the time of first vaccination until 3 months after last vaccination. <br/ >9. Agrees not to participate in another clinical trial at any time during the study. <br/ >10. Agrees to remain in the study area for the entire duration of the study. <br/ >11. Willing to allow storage and future use of biological samples for future research. <br/ >

<br/ >1. Ability to provide written informed consent. <br/ >2. Participants of either gender of age between �18 to �60 years. <br/ >3. Good general health as determined by the discretion of investigator (vital signs (heart rate �60 to�100 bpm, blood pressure systolic �90 mm Hg and <140 mm Hg, diastolic � 60 mm Hg and <90 mm Hg, oral temperature <100.4ºF), medical history, and physical examination). <br/ >4. Expressed interest and availability to fulfil the study requirements. <br/ >5. For a female participant of child-bearing potential, planning to avoid becoming pregnant (use of an effective method of contraception or abstinence) from the time of study enrolment until at least four weeks after the last vaccination. <br/ >6. Male subjects of reproductive potential: Use of condoms to ensure effective contraception with the female partner from first vaccination until 3 months after last vaccination. <br/ >7. Male subjects agree to refrain from sperm donation from the time of first vaccination until 3 months after last vaccination. <br/ >8. Participants must refrain from blood or plasma donation from the time of first vaccination until 3 months after last vaccination. <br/ >9. Agrees not to participate in another clinical trial at any time during the study. <br/ >10. Agrees to remain in the study area for the entire duration of the study. <br/ >11. Willing to allow storage and future use of biological samples for future research. <br/ >

<br/ >1. Ability to provide written informed consent. <br/ >2. Participants of either gender of age between �18 to �60 years. <br/ >3. Good general health as determined by the discretion of investigator (vital signs (heart rate �60 to�100 bpm, blood pressure systolic �90 mm Hg and <140 mm Hg, diastolic � 60 mm Hg and <90 mm Hg, oral temperature <100.4ºF), medical history, and physical examination). <br/ >4. Expressed interest and availability to fulfil the study requirements. <br/ >5. For a female participant of child-bearing potential, planning to avoid becoming pregnant (use of an effective method of contraception or abstinence) from the time of study enrolment until at least four weeks after the last vaccination. <br/ >6. Male subjects of reproductive potential: Use of condoms to ensure effective contraception with the female partner from first vaccination until 3 months after last vaccination. <br/ >7. Male subjects agree to refrain from sperm donation from the time of first vaccination until 3 months after last vaccination. <br/ >8. Participants must refrain from blood or plasma donation from the time of first vaccination until 3 months after last vaccination. <br/ >9. Agrees not to participate in another clinical trial at any time during the study. <br/ >10. Agrees to remain in the study area for the entire duration of the study. <br/ >11. Willing to allow storage and future use of biological samples for future research. <br/ >